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CRISPR/Cas9 Technology in Pig 
Research
Huafeng Lin, Qiudi Deng, Lili Li and Lei Shi
Abstract
Pigs provide valuable meat sources, disease models, and research materials 
for humans. However, traditional methods no longer meet the developing needs 
of pig production. More recently, advanced biotechnologies such as SCNT and 
genome editing are enabling researchers to manipulate genomic DNA molecules. 
Such methods have greatly promoted the advancement of pig research. Three 
gene editing platforms including ZFNs, TALENs, and CRISPR/Cas are becoming 
increasingly prevalent in life science research, with CRISPR/Cas9 now being the 
most widely used. CRISPR/Cas9, a part of the defense mechanism against viral 
infection, was discovered in prokaryotes and has now developed as a powerful 
and effective genome editing tool that can introduce and enhance modifications 
to the eukaryotic genomes in a range of animals including insects, amphibians, 
fish, and mammals in a predictable manner. Given its excellent characteristics 
that are superior to other tailored endonucleases systems, CRISPR/Cas9 is suitable 
for conducting pig-related studies. In this review, we briefly discuss the histori-
cal perspectives of CRISPR/Cas9 technology and highlight the applications and 
developments for using CRISPR/Cas9-based methods in pig research. We will 
also review the choices for delivering genome editing elements and the merits and 
drawbacks of utilizing the CRISPR/Cas9 technology for pig research, as well as 
the future prospects.
Keywords: applications, CRISPR/Cas9, delivery methods, gene editing, pig
1. Introduction
1.1  The status of pig production and current application of CRISPR/Cas9 
technology
Worldwide, pig (Sus scrofa domestica) production accounted for 42% of total 
livestock production in 2018, and this percentage is expected to go up by the 
year 2050 [1, 2]. Pork, which makes up nearly 40% of all meat consumed by the 
world population, is clearly an important meat source for humans [3]. These 
production and consumption data reveal the significant implications of pigs 
for humans. Indeed, pigs bring many benefits for the convenience and survival 
of human beings. In light of the importance and necessity for pig production, 
researchers all around the world are using various methods to actively investigate 
this species.
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Benefitting from the rapid development of genome-editing technologies during 
the last decade, many laboratories have applied this tool to animals, plants, and 
microorganisms in order to obtain both higher yield and better quality varieties. 
With the advent of the CRISPR (clustered regularly interspaced short palindromic 
repeats)/Cas9 technique and the melioration of delivery methods, gene editing can 
be more successfully performed in livestock such as swine. In addition, evidence 
shows that, in addition to primates, pigs share many similar characteristics with 
humans such as organ size, genome length, blood glucose levels, and the complexity 
and composition of chromosomes [4, 5], as well as the early embryonic develop-
ment trajectory [6]. Therefore, pigs are not only used as important domestic 
animals for food and pharmaceutical applications, but also served as ideal animal 
models for simulating various human diseases (e.g., diabetes, obesity, and cardio-
vascular disease). In this manuscript, we first introduce the historical perspectives 
of gene-editing technologies in pigs, review the latest advances in the utilization of 
CRISPR/Cas9 strategies for swine research, and then describe possible methods for 
delivering these genome-editing components, as well as the future perspective on 
pig studies by using this technology.
1.2 Historical background of gene editing in pigs
CRISPR, discovered in 1987, is a family of DNA sequences of short direct 
repeats interspaced with short sequences. Its mechanism of action has been 
confirmed to be related with acquired immunity of microbes [7–9]. By 2000, 
researchers had discovered that these specific sequences occurred in about 40% 
of bacteria and 90% of archaea [10, 11]. In 2002, this interesting architecture, 
initially named short regularly spaced repeats (SRSRs), was renamed as the 
clustered regularly interspaced short palindromic repeats (CRISPRs) [10, 12]. 
Between 2002 and 2009, a series of proteins associated with these palindromic 
sequences were identified as constituents of the complicated mechanism of 
microbial adaptive immunity [11]. In 2014, the X-ray crystal structure of 
Streptococcus pyogenes Cas9 (SpCas9) in complex with sgRNA was elucidated  
[13, 14]. Nowadays, SpCas9 endonuclease, which requires a protospacer adjacent 
motif (PAM) sequence (5’-NGG-3′), is routinely designed as a ‘molecular scis-
sor’ guided by a single guide RNA (or dual-tracrRNA) due to simple structural 
characteristics, the advantages of easy operation, and high efficiency [11, 15]. 
Notably, the multiplex abilities of the Cas9-associated guided RNAs (gRNAs) and 
the diverse Cas9 orthologs (e.g., SpCas9, SaCas9, StCas9) as well as the diversified 
Cas9 variants (Figure 1) have enabled CRISPR/Cas9 systems to be used in a wide 
range of research applications [16, 17].
As early as 1985, the first transgenic pig was created by direct DNA microinjec-
tion of the metallothionein-I/human growth hormone (MT/hGH) fusion gene into 
a fertilized egg [18]. Further technical enhancements occurred during the next 
20 years, until, in 2011, Whitworth and his co-workers were the first to success-
fully apply ZFN technology to generate cloned eGFP knockout pigs [19]. Similarly, 
Carlson et al. (2012) pioneered the application of TALENs in editing the porcine 
genome, and they produced low-density lipoprotein receptor (LDLR) knockout 
pigs [20]. By 2013, the groundbreaking work of genome engineering in mam-
malian cells based on the CRISPR/Cas9 system had been achieved [21]. The first 
examples of genome-modified pigs engineered using the CRISPR/Cas9 technique 
were reported almost simultaneously by Hai et al. (2014) [22] and Whitworth et al. 
(2014) [23]. From then on, rapid and efficient CRISPR/Cas9-mediated genome 
editing in pigs has opened up many more possibilities for applications in biology 
and biomedicine.
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2. Application and development
2.1 Applications in the antimicrobial and antiviral fields
Currently, the traditional methods for developing pig anti-viral vaccines are 
time-consuming and labor-intensive [24]. Cas9 endonucleases, as molecular DNA 
scissors guided by gRNA, are now used to target and cut exogenous DNA arising 
from virus or plasmids [25]. With the development of state-of-the-art biotechnolo-
gies, scientists now can utilize this revolutional tool to prevent domestic pigs from 
pathogenic bacterial and viral attack. In 2016, Liang and his colleagues developed a 
rapid vaccine development method based on the combination of CRISPR/Cas9 and 
the Cre/Lox system to fight against the re-emerging pseudorabies virus (PRV). The 
results demonstrated the protective efficacy of this candidate vaccine in swine and 
showed promise in controlling the outbreak of pseudorabies [26]. In another trial, 
Whitworth et al. (2015) employed the CRISPR/Cas9 system to directionally mutate 
the CD163 gene (cluster of differentiation 163 gene, a gate keeper gene associated 
with PRRSV) in order to create biallelic gene knockout pigs which had protective 
immunity against infection of porcine reproductive and respiratory syndrome 
virus (PRRSV) [27]. In 2018, Xie and his co-workers applied the combinational 
method of CRISPR/Cas9 and RNAi to generate anti-CSFV transgenic pigs and 
confirmed that these pigs could impede the multiplication of classical swine fever 
virus (CSFV). They further proved that the disease resistance traits presented in the 
Figure 1. 
Diagram illustrating different types of engineered CRISPR/Cas9 and its Cas9 variants. (A) The wild-type 
SpCas9 nuclease. (B) The wild-type SaCas9 nuclease. (C) The wild-type NmCas9 nuclease. (D) The wild-
type StCas9 nuclease. (E) The dCas9 variant can bind DNA but cannot cut DNA strands. (F) The SpCas9 
nickase that can only introduce a single strand break at the HNH nuclease domain. (G) The SpCas9 nickase 
that can only introduce a single strand break at the RuvC nuclease domain. (SpCas9, Streptococcus pyogenes 
Cas9; SaCas9, Staphylococcus aureus Cas9; NmCas9, Neisseria meningitides Cas9; StCas9, Streptococcus 
thermophilus Cas9; dCas9, catalytically inactive (“dead”) Cas9; sgRNA, single-guide RNA; PAM, protospacer 
adjacent motif; W = A or T). Refer to [16].
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transgenic sows could be stably transmitted to their F1-generation offspring. This 
study suggested that the use of such transgenic pigs would offer potential benefits 
over commercial vaccination, could substantially reduce CSFV-related economic 
losses, and would also improve the well-being of livestock [28]. Compared to CSFV, 
African swine fever virus (ASFV) is a very acute, lethal viral pathogen for both 
domestic and wild pigs, but unfortunately, a vaccine candidate that effectively 
prevents ASFV infection remains elusive. HüBner et al. (2018) applied the CRISPR/
Cas9 nuclease system to target the double-stranded DNA genome of ASFV. In vitro 
culture experiments showed that mediated targeting of the ASFV p30 gene using 
this system is a feasible strategy to fight against ASFV infection, and may also be 
applied to the natural animal host [29].
2.2 Applications to breeding and reproduction
Traditional breeding methods, which comprise selective breeding and cross-
breeding, have clearly hit a bottleneck. Additionally, due to the long time, high cost, 
and high labor intensity of traditional breeding methods [30], researchers now 
hope to find other alternatives that are more convenient and efficient than previ-
ously. Genome-editing technology can help us to achieve a good result in a short 
time, and help better understand swine reproduction. Interestingly, many aspects 
of pig reproduction are suitable as translational models of reproduction in humans, 
including oocyte maturation, sperm-egg interaction mechanism, tubo-uterine 
contractility, early embryo development, pregnancy, fetal genome modification, 
and reproductive diseases [31]. Strategies that use the CRISPR/Cas9 technique to 
improve the reproduction in swine are becoming more prevalent. PRRSV, a virus 
associated with reproductive and respiratory disease, can cause severe unsuccessful 
reproductive outcomes in sows, decrease sperm quality in infected boars, and lower 
the birth rates of healthy piglets [32]. In 2016, Tao et al. generated efficient biallelic 
mutation in porcine parthenotes by cytoplasmic injection of Cas9/sgRNA mixtures. 
These data emphasize the function of parthenotes in revealing early embryonic 
development and assessing mutation efficiency [33]. In the same year, Whitworth 
et al. used CRISPR/Cas9 to generate CD163-knockout pigs to protect pig from 
PRRSV and reduce the incidence of reproductive disease, important for pig studies 
in both the fields of reproduction and anti-viruses [27]. In 2017, Park et al. utilized 
CRISPR/Cas9 technology to program the NANOS2 gene in domestic pigs to gener-
ate offspring with monoallelic and biallelic mutations. They found that NANOS2 
knockout pigs presented the phenotype of male specific germ line ablation but 
other aspects of testicular development were normal. The exception was male pigs 
with one intact NANOS2 allele and female knockout pigs which both maintained 
good reproductive performance [34].
2.3 Applications in immunization and xenotransplantation
Swines, having many highly similar anatomical and physiological features 
to humans, are considered to be the excellent donors for patients in the case of a 
shortage of human organs for allogenic transplantation [35, 36]. However, several 
issues still need to be addressed such as hyperacute rejection which can develop in 
recipients within several minutes after organ xenotransplantations [36, 37]. The 
advancement of the CRISPR/Cas9 technique has greatly strengthened the ability 
to effectively manipulate porcine genome in order to evaluate and generate porcine 
organs that can assist in xenotransplantation.
An early study, undertaken by Sato and his research team in 2013, used a modi-
fied CRISPR/Cas9 system to knockout the porcine GGTA1 gene, whose protein 
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product is responsible for the biosynthesis of the a-Gal epitope, which leads to 
hyperacute rejection upon pig-to-human xenotransplantation. This trial not only 
demonstrated that CRISPR/Cas9 is a promising tool for producing knockout cloned 
piglets, but also paved the way for pig-to-human xenotransplantation [38]. Piglets 
with biallelic knockouts of GGTA1 gene were eventually created by Petersen and his 
colleagues [39] using the combined technologies of CRISPR/Cas9 and somatic cell 
nuclear transfer (SCNT).
Swine could also serve as an ideal animal model for investigating viral immu-
nity and immune rejection in xenotransplantation if they are deficient in class I 
MHC. Research published by Reyes et al. in 2014 utilized the Cas9 endonuclease 
with chimeric gRNAs to generate class I MHC knockout piglets as promising 
experimental animals for immunological research [40]. In 2015, Yang and co-
workers designed two Cas9 gRNA molecules to inactivate 62 copies of the pol gene 
required for porcine endogenous retrovirus (PERV) activity. This study performed 
on porcine kidney epithelial cell lines demonstrated that the modifications could 
greatly reduce in vitro spreading of PERVs to human cells, raising the hope of the 
eradication of such viruses from pigs for heterograft donors [41]. One year later, 
Yang’s research team (2017) made further progress in employing CRISPR/Cas9 
technology to inactivate all the PERVs in a porcine primary cell line and produced 
PERV-eliminated pigs using the SCNT technique. The experimental results 
addressed the safety problem in clinical xenotransplantation due to the success of 
impeding interspecific transmission of viruses [42].
2.4 Disease models and translational medical research
The CRISPR/Cas9 technology has both simplified and expedited biomedical 
modeling for some refractory human diseases. One way to combat human diseases 
is to create genetically modified animal models for investigating the mechanism 
of diseases enabling the development of safe and effective drugs. An effective 
animal disease model should appropriately simulate the in vivo environment under 
investigation and respond or react to stimuli in a similar manner to the human body 
[43–45]. Commonly used animal models in the laboratory include mice, rats, dogs, 
monkey, and swine. The pig models have been developed to faithfully mimic vari-
ous human diseases including neurodegenerative diseases [46], cancers [45], and 
gastrointestinal (GI) tract diseases [47] as they share similar features to humans in 
terms of anatomy, physiology, and genetics [43]. Gene editing using CRISPR/Cas9 
technology is proving an innovative and effective research tool, which is greatly 
revolutionizing our ability to manipulate the porcine genome to create appropriate 
disease models.
As early as 2013, Tan et al. used two custom endonucleases (TALEN and 
CRISPR/Cas9 system) to edit azoospermia-like (DAZL) and adenomatous polyposis 
coli (APC) loci in the pig genome. The results suggested that gene editing could 
be incorporated into selection programs to accelerate genetic improvement, with 
applications in animal breeding and human personalized medicine [48]. In 2014, 
Zhou et al. were the first to report that zygote injection of a customized CRISPR/
Cas9 system could efficiently generate genome-modified pigs (biallelic knockout 
pigs) in one step, which provided an important animal model for the treatment of 
human type I and III von Willebrand disease [22]. At the end of 2015, Peng et al. 
adopted the CRISPR/Cas9 method to knockin human cDNA into the albumin 
gene locus in pig zygotes and successfully produced human albumin from porcine 
blood [49]. Additionally, Feng et al. (2015) reported the potential of using the 
combination of CRISPR/Cas9 and human pluripotent stem cells (PSCs) to harvest 
human organs from chimeric swine [50]. In 2016, Wang et al. performed a study in 
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which Cas9 mRNA and multiple single guide RNAs (sgRNAs), which respectively 
specifically target to parkin, DJ-1, and PINK1 gene loci, were coinjected into in vivo 
derived pronuclear embryos of Bama miniature pigs. There were only minor low 
off-target events. These results demonstrated the capability of using the CRISPR/
Cas9 system to trigger genetic modification of multiple sites in pigs, yielding 
positive results with high medical value [51]. In the same year, Lee and his team 
utilized genome-specific CRISPR/Cas9 systems to target runt-related transcription 
factor 3 (RUNX3, a known tumor suppressor gene) to generate a pig model that can 
recapitulate the pathogenesis of RUNX3-associated stomach cancer in humans. The 
results demonstrated that the CRISPR/Cas9 system was effective in inducing muta-
tions on a specific locus of the pig genome, resulting in the generation of piglets 
lacking RUNX3 protein in their internal organs. This system brings useful resources 
(RUNX3 knockout pigs) for human cancer research and the development of novel 
cancer therapies [52]. In 2017, Zhang et al. designed an experiment that applied the 
CRISPR/Cas9 system and SCNT technology to generate complement protein C3 
targeted piglets, which could be a valuable large animal model for elucidating the 
roles of C3, a protein of the immune system that plays a central role in the comple-
ment system and contributes to innate immunity [53]. By 2018, following many 
years’ efforts, scientists have now made significant progress in using CRISPR/Cas9-
mediated knockin techniques to produce a Huntington’s disease (HD) pig model, 
which assists in the investigation of the pathogenesis of neurodegenerative diseases 
and the development of appropriate therapeutics [54]. Recently (2018), Cho and 
co-workers successfully used the CRISPR/Cas9 and SCNT technologies to gener-
ate INS knockout pigs (insulin-deficient pigs) and demonstrated the efficacy of 
the CRISPR/Cas9 system in producing pig models for use in diabetes research and 
pharmaceutical testing [55].
2.5 Improvement of meat quality and food safety
Pig meat quality is controlled by multiple factors. To some extent, genetics are 
considered as the dominating factor influencing pork quality in the pig industry, 
although environmental conditions can also potentially influence the porcine genet-
ics in the long term. In addition, fat and lean meat contents are both important for 
the palatability of the pork [56, 57] and diet considerations. Consequently, scientists 
now propose to improve pork traits to cater for the taste of the general public by 
using gene-editing technology. In 2016, Bi et al. constructed isozygous, functional 
myostatin (MSTN) knockout cloned pigs without selectable marker gene (SMG) by 
combined use of CRISPR/Cas9 and Cre/LoxP. The results showed that compared 
to the control group, the skeleton muscles were more pronounced and the back 
fat thickness decreased slightly in such gene-edited pigs [58]. In 2017, Zheng et al. 
established a CRISPR/Cas9-mediated homologous recombination-independent 
approach to efficiently insert mouse adiponectin-UCP1 into the porcine endog-
enous uncoupling protein 1 (UCP1) locus. The resultant UCP1 knockin pigs showed 
an enhanced ability to control their body temperature during acute cold exposure, 
lower fat deposition, and increased carcass lean meat [59]. In 2018, Xiang et al. used 
CRISPR/Cas9 technology to effectively edit insulin-like growth factor 2 (IGF2) 
intron 3–3072 site as the method of choice for the improvement of meat production 
in Bama pigs. The result showed that it was the first time to demonstrate that edit-
ing a noncoding region can ameliorate economic traits in livestock [60].
CRISPR/Cas9 gene-editing technology has multiple benefits. In gene detection 
fields, Zhou et al. developed a CRISPR/Cas9-triggered nicking endonuclease-
mediated strand displacement amplification method (namely CRISDA) for 
amplifying and detecting double-stranded DNA [61]. CRISDA promises to be a 
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Authors/year/refs Cells/organisms Genomic loci CRISPR/
Cas9 delivery 
platforms
Gene-editing 
modes
CRISPR/Cas9 formats Comments/results
Hai et al., 2014, [22] Zygote vWF Cytoplasmic 
injection
Knockout Cas9 mRNA and 
sgRNA
Constructed pig disease modes using 
CRISPR/Cas9
Sato et al., 2014, [38] PEFs GGTA1 Plasmids/
transfection
Knockout/
CNT
CRISPR/Cas9 plasmids 
DNA and sgRNA
Efficiently mutated portion of GGTA1
Whitworth et al., 2014, 
[23]
PFF cells eGFP/CD163/CD1D Plasmids/
transfection/
microinjection
Knockout Cas9 plasmids DNA 
and sgRNA
Generated GE pigs for mutating two 
genes
Chen et al., 2015, [68] PFFs JH Plasmids/
transfection/
electroporation
Knockout/
SCNT
Cas9-sgRNA plasmids Generated a B cell-deficient phenotype 
in pig
Li et al., 2015, [69] Liver-derived cells GGTA1/CMAH/
iGB3S
Plasmids/
transfection
Knockout/
SCNT
Cas9 plasmids and 
multiplexed sgRNA
Modified multiple genetic in a single 
pregnancy
Peng et al., 2015, [49] Zygotes Alb Microinjection Knockin Cas9 mRNA and 
sgRNA
Knockined Alb gene and produced 
albumin in the blood of piglets
Ruan et al., 2015, [63] PFFs pH11 Plasmids/
electroporation
Knockin Cas9/sgRNA targeting 
plasmids
Inserted foreign gene into the pH11 
locus
Wang et al., 2015, [70] Oocytes/PPFs MITF Microinjection Knockout/
knockin
Cas9 mRNA and 
sgRNA
Expanded the practical possibilities 
in pigs
Zhou et al., 2015, [64] PFFs TYR/PARK2 /PINK1 Plasmids/
transfection
Knockout/
SCNT
Cas9 plasmids and 
sgRNA
Gene-targeted pigs can be effectively 
achieved
Kang et al., 2016, [52] PFFs RUNX3 Plasmids/
transfection/
electroporation
Knockout Cas9-sgRNA plasmids Generated pig disease mode for cancer 
research
Petersen et al., 2016, [39] Oocytes GGTA1 Intracytoplasmic 
microinjection
Knockout (Cas9 and sgRNA) 
expression DNA
GGTA1 knockout pigs could bring 
xenotransplantation closer to clinical 
application
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Authors/year/refs Cells/organisms Genomic loci CRISPR/
Cas9 delivery 
platforms
Gene-editing 
modes
CRISPR/Cas9 formats Comments/results
Wang et al., 2016, [51] Zygotes parkin/DJ-1/PINK1 Co-injection Knockout Cas9 mRNA and 
multiplexing sgRNAs
Modified multiple genes in pigs
Yang et al., 2016, [65] PFFs pINS Plasmids/
electroporation
SCNT Cas9 plasmids/sgRNA Generated the genetically modified pigs 
exclusively expressing human insulin
Yu et al., 2016, [73] Zygotes DMD Plasmids/
microinjection
Knockout Cas9 mRNA and 
sgRNA
Targeted of DMD gene in miniature pig
Chuang et al., 2017, [71] Fertilized eggs GGTA1 Plasmids/
microinjection
Knockout CRISPR/Cas9 plasmids 
DNA
Firstly used porcine U6 promoter to 
express gRNA to generate GGTA1 
mutant pigs with PBMCs
Gao et al., 2017, [74] PFFs GGTA1/CMAH Plasmids/
handmade 
cloning (HMC)
Knockout Cas9-coding DNA and 
sgRNA
Modified multiple genes in pigs
Huang et al., 2017, [75] PEFs ApoE/LDLR Plasmids/
electroporation
Knockout/
SCNT
(Cas9 and sgRNA) 
expression DNA
Generated genetically modified pigs 
targeting the ApoE and LDLR genes 
simultaneously
Li et al., 2017, [76] Oocytes/PFFs TPH2 Plasmids/
electroporation
Knockout/
SCNT
(Cas9 and sgRNA) 
expression DNA
Tph2 targeted piglets were successfully 
generated
Park et al., 2017, [34] Oocytes NANOS2 Plasmids Knockout Cas9:GFP mRNA and 
sgRNA
Edited the NANOS2 gene to generate 
germline ablated male pigs
Whitworth et al., 2017, 
[72]
Zygote TMRPSS2 Plasmids/
microinjection
Mutation sgRNA and Cas9 
mRNA
Successfully modified the target gene
Wu et al., 2017, [77] Oocytes PDX1 Microinjection Knockin Cas9 mRNA and dual 
sgRNAs
Xeno-generated of human tissues and 
organs in pigs
Zheng et al., 2017, [59] FFAs UCP1 Plasmids Knockin Cas9-sgRNA plasmids Improves pig welfare and reduces 
economic losses
Borca et al., 2018, [78] Primary swine 
macrophage
8-DR Plasmids Targeted 
deletion
Cas9 plasmids/sgRNA Used CRISPR-Cas9 system to produce 
recombinant ASFVs
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Authors/year/refs Cells/organisms Genomic loci CRISPR/
Cas9 delivery 
platforms
Gene-editing 
modes
CRISPR/Cas9 formats Comments/results
Cho et al., 2018, [55] Porcine primary 
fibroblasts
INS Plasmids/
electroporation
Knockout Cas9:GFP mRNA and 
sgRNA
Demonstrated effectiveness of CRISPR/
Cas9 in generating new pig models
Hübner et al., 2018, [29] ASFV-permissive 
WSL cells
CP204L Plasmids Targeted 
deletion
(Cas9 and sgRNA) 
expression DNA
CRISPR/Cas9 mediated targeting of 
the ASFV p30 gene is a valid strategy to 
convey resistance against ASF infection
Santos et al., 2018, [79] Pig aortic 
endothelial cells
pTHBD Plasmids Knockout/
recombination
(Cas9 and sgRNA) 
expression DNA
Create pigs with human genes in 
orthotopic position (hTHBD was 
inserted into the pTHBD locus)
Sato et al., 2018, [80] zygote GGTA1 Microinjection Knockout Cas9 mRNA and 
sgRNA; plasmid 
encoding humanized 
Cas9 and sgRNA
Developing a technique that reduces 
mosaicism is a key factor for production 
of knockout pigs
Xie et al., 2018, [28] Porcine kidney 
cell/PFFs
Porcine ROSA26 Plasmids/
electroporation
Knockin/
SCNT
(Cas9 and sgRNA) 
expression DNA
Successfully produced anti-CSFV pigs
Yan et al., 2018, [54] PFFs HTT Plasmids/
electroporation
Knockout/
SCNT
(Cas9 and sgRNA) 
expression DNA
First time to produce HD pig models 
for investigating the pathogenesis of 
neurodegenerative diseases
Yang et al., 2018, [81] PFFs CD163 Plasmids/
electroporation
Knockout/
SCNT
(Cas9 and sgRNA) 
expression plasmids
Demonstrated that CD163 knockout 
confers full resistance to HP-PRRSV 
infection to pigs
Acronyms and abbreviations: apolipoprotein E (ApoE); albumin (Alb); cysteine-rich domain 163 (CD163); CMP-Neu5Ac Hydroxylase (CMAH); duchenne muscle dystrophy (DMD); huntingtin (HTT); 
insulin (INS); microphthalmia-associated transcription factor (MITF); pancreatic duodenal homeobox-1 (PDX-1); porcine aortic endothelial cells (pAECs); porcine fetal fibroblasts (PFFs); pig embryonic 
fibroblast cells (PEFs); PTEN-induced kinase 1 (PINK1); Huntington’s disease (HD); runt-related transcription factor 3 (RUNX3); thrombomodulin (THBD); tryptophan hydroxylase 2 (TPH2); 
transmembrane protease, serine 2 (TMPRSS2); tyrosinase (TYR); von Willebrand factor (vWF); wild boar lung (WSL).
Table 1. Examples for the applications of CRISPR/Cas9 technology in pigs.
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powerful isothermal tool for ultrasensitive and specific detection of nucleic acids in 
pig pathogeny detection and food safety. Consequently, by making good use of this 
precision editing engineered technology in agriculture, a reliable avenue for elite 
swine production could be guaranteed, potential biological risks can be minimized, 
and a higher food safety can be protected.
2.6 Applications in transgenesis and beyond
Pig transgenesis is an important facet for functional investigation of biological 
pathways, as well as for biotechnology in animal husbandry. As a promising tool, 
CRISPR/Cas9 now has the ability to accelerate the process of pig transgenesis. 
Several studies have successfully constructed a CRISPR/Cas9 system for targeting 
the pig GGTA1 gene [38, 39, 62]. Ruan et al. (2015) inserted a gene fragment larger 
than 9 kb at the newly named pH 11 genomic locus using CRISPR/Cas9 technology 
and then confirmed that it was highly expressed in cells, embryos, and animals 
[63]. Similarly, Zhou et al. (2015) worked on CRISPR/Cas9-mediated gene target-
ing in porcine fetal fibroblasts (PFFs), in which TYR, PARK2, and PINK1 loci were 
effectively edited [64]. In 2016, Yang and colleagues edited the porcine INS (pINS) 
gene in fibroblasts by using TALENs or CRISPR/Cas9 [65], and in 2017, Zheng et al. 
inserted a mouse adiponectin-UCP1 gene efficiently into the porcine endogenous 
UCP1 locus by the utilization of a CRISPR/Cas9-mediated homologous recombina-
tion-independent approach [59]. In the same year, Wang et al. applied the com-
bined system of Cre recombinase and Cas9/sgRNAs to simultaneously inactivate 
five tumor suppressor genes (TP53, PTEN, APC, BRCA1, and BRCA2) and activate 
one oncogene (KRAS) to develop a rapid lung tumor model in pigs [66]. By 2018, 
Whitworth et al. had developed a method that utilized the CRISPR/Cas9 technol-
ogy to remove a loxP flanked neomycin cassette by direct zygote injection of RNA 
encoding Cre recombinase. This new technique can be used to efficiently remove 
selectable markers in genetically engineered animals without the need for long-term 
cell culture and subsequent somatic cell nuclear transfer (SCNT) [67]. Almost 
certainly, it has a very promising future for transgenic pigs with the advantages of 
enhancing body growth and minimizing environmental pollution that would be 
created by the CRISRP/Cas9 method. Table 1 shows applications of CRISRP/Cas9 
technology in transgenic pigs.
3. Delivery methods of CRISPR/Cas9
3.1 The appropriate choices for delivery: viral systems or nonviral platforms?
In order to introduce precise and efficient genome modification, the proper 
delivery modalities of CRISPR/Cas9 genome-editing materials are a crucial factor in 
the generation of genetically engineered pigs. A variety of strategies have been used 
for delivering the CRISPR/Cas9 system which can be mainly divided into viral and 
nonviral delivery methods (Figure 2) [82].
Viral systems are the traditional tools that have been widely used for deliv-
ering genome editing materials (DNA or mRNA). To-date, three viral vectors 
including lentivirus [83], adenovirus, and adeno-associated virus (AAV) have 
been used for delivery of CRISPR/Cas9 components in various biological stud-
ies [84, 85]. However, there are several limitations associated with viral vectors 
including immunogenicity, packaging capacity, broad tropism, and difficulty 
in production.
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Nonviral platforms for transferring the CRISPR/Cas9 components can be 
achieved by physical and chemical approaches. In contrast to viral vectors, non-
viral vectors have lower immunogenicity, are not constrained by packaging sizes, 
are facile to synthesize, and are capable of carrying multiple sgRNAs simultane-
ously [86, 87]. In nonviral methods, genome editing reagents are delivered either 
as mRNA or as a combination of Cas9 endonuclease and sgRNA. To date, nonviral 
methods available include microinjection, electroporation [88], hydrodynamic 
injection, lipid particles, nanoclews, zwitterionic amino lipid (ZAL) nanopar-
ticles, and iTOP as well as the combinations of viral and nonviral methods [82]. 
Herein, we compared the various methods for delivering the CRISRP/Cas9 system 
(Table 2).
Delivery methods of gene modification in the field of pig research have even 
used sperms as vectors for foreign genes (e.g. sperm-mediated gene transfer 
(SMGT), and intracytoplasmic sperm injection (ICSI)-mediated gene transfer), 
and delivery strategies such as retroviruses and lentiviruses are still current [100]. 
Somatic cell nuclear transfer (SCNT), a technique that consists of taking an enucle-
ated oocyte and then implanting a donor nucleus from a somatic cell, is a remark-
able breakthrough in the history of swine genetic engineering [101, 102]. SCNT 
combined with the rapid development of gene editing technologies such as TALENs 
and CRISPR/Cas9 has excellent prospects.
3.2 Challenges for delivering the CRISPR/Cas9 systems
The CRISPR/Cas9 system has been applied to genome modification in a variety 
of microorganisms, plants, and animals (including pigs), but the efficient transfer 
of such system is still a challenge that affects the precise genome-editing activ-
ity [103]. If the CRISPR/Cas9 systems are to effectively function in the targeted 
cells or organisms, choosing a suitable delivery system is of critical importance. 
According to existing research, the CRISPR/Cas9 system can be broadly divided 
into three kinds of packaging formats: Cas9 protein and sgRNA, Cas9 mRNA and 
Figure 2. 
Delivery techniques for the CRISPR/Cas9 system. (iTOP: induced transduction by osmocytosis and 
propanebetaine; AAV: adeno-associated virus).
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sgRNA, and CRISPR/Cas9 plasmid. Different CRISPR/Cas9 formats cooperate 
with special transport vehicle to complete the transportation task for gene-editing 
elements. Some research studies indicate that CRISPR/Cas9 ribonucleoprotein 
(RNP) delivery seems to exceed gene delivery as it provides multiple function 
advantages: short-term delivery, no insertional mutagenesis, minimal immuno-
genicity, and low off-target effect [87]. As previously mentioned, viral vectors 
usually have their own limitations to be overcome compared to nonviral vectors. 
However, nonviral vectors are generally used for in vitro genome editing studies 
due to their biological incompatibility or cytotoxicity [95]. Recently, developing 
efficient and biocompatible nonviral vectors (e.g., liposome and nanocarrier) has 
just emerged, and achievements have been made. For example, a low cytotoxic 
cationic polymer has been proven to mediate efficient CRISPR/Cas9 plasmid 
delivery for genome editing [92]. In addition, a research article presented that 
lipid-based Cas9 mRNA delivery has lower off-target effects than lentivirus- 
packaged Cas9 mRNA transportation [104]. Generally speaking, the packag-
ing modes and delivery tools are two biggest factors that affect efficiency of 
the CRISPR/Cas9 system apart from this system itself. In order to describe the 
possible challenges for delivering the CRISPR/Cas9 system and the strategies used 
to overcome these challenges, we form a table to illustrate in detail (Table 3) and 
further to promote much research applications appropriately.
Delivery modes Advantages Limitations Text 
refs
Lentivirus Broad cell tropism; large 
capacity; long-term gene 
expression
Prone to insertional mutagenesis; 
transgene silencing; potential in 
carcinogenesis
[84], 
[89],
[87], 
[90]
Adenovirus High efficiency and versatility Difficult to manufacture in scale; 
immunogenicity
[84], 
[91]
Adeno-associated 
virus
Minimal immunogenicity; 
non-pathogenic
Limited packaging size; potential 
to cause significant genomic 
damage
[14], 
[92], 
[93]
Electroporation High transfection efficiency; 
suitable for all types of 
CRISPR-Cas9
Cytotoxicity; difficult for in vivo 
use
[94], 
[95]
Hydrodynamic 
delivery
Virus-free; easy-to-use; 
low-cost
Non-specific; tissue-invasive [89], 
[96], 
[97]
Microinjection Highly specific and 
reproducible
Time-consuming; suitable 
for in vitro applications; 
low-throughput
[94], 
[87]
Polymer 
nanoparticles
Safe; low-cost; simple 
manipulation; greater 
encapsulation capability
Low delivery efficiency [94], 
[92]
Gold nanoparticles Membrane-fusion-like delivery Nonspecific inflammatory 
response; potential toxicity
[89], 
[98]
iTOP Use for the delivery of Cas9 
protein and sgRNA
Need to master sophisticated 
operating skills
[84], 
[89]
Nanoclews Virus-free Need to modify the template 
DNA
[99]
Table 2. 
Comparison of different delivery methods for CRISPR/Cas9 system.
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4. Discussion
CRISPR/Cas9 technology is not only simple and easy to perform, but also has 
significantly improved performances for mutational studies, which has accelerated 
the application of the CRISPR/Cas9 toolkit [68, 111]. However, there are still some 
limitations and difficulties in the use of the CRISPR/Cas9 system for pig research.
1. The CRISPR/Cas9 system itself is not flawless, and its off-site concerns vary in 
different biological species [112, 113]. In addition, if the design and construc-
tion of sgRNA are not ideal, off-target editing of the genomic DNA can easily 
occur. With more available datasets of CRISPR/Cas9, more newfangled tools 
for designing sgRNA will be developed to lower the off-target effects.
2. In pigs, complex traits associated with multiple genes enhance the difficulties 
of using CRISPR/Cas9 to simultaneously and precisely edit and program DNA 
in the porcine genome.
3. Complex environmental factors including water sources and feed qualities, as 
well as animal husbandry production methods, as a range of external stimuli, 
could collaboratively affect CRISPR/Cas9-derived pigs in the long-term.
4. Strategies and timing for delivering CRISPR/Cas9 systems need to be opti-
mized to control the ratio of HDR to NHEJ in order to enhance the efficiency 
of homology-directed recombination (HDR)-mediated precise gene modifica-
tion [105].
Challenges Delivery methods Strategies Text 
refs
Off-target effects Both in viral and nonviral 
vectors; using plasmid-
based system
Engineering high specificity Cas9 
protein; optimizing sgRNA design; 
proper selection of targeting site
[105], 
[94]
Packaging challenges AAV (~4.7kpb), adenovirus, 
lentivirus (~10kpb)
Nonviral vectors have no packaging 
limitation, easy to prepare, and low 
in cost
[87], 
[106]
Insertional 
mutagenesis
AAV, adenovirus, lentivirus, 
retrovirus
Using Cas9−RNP for delivering; 
improved specificity
[87], 
[93], 
[107]
Mosaic genotypes Microinjection Stimulating the HDR pathway; use 
of Cas9 nickase
[108]
Immunogenicity AAV, adenovirus, lentivirus, 
retrovirus
Using nonviral vectors to lower 
immunogenicity
[87], 
[95], 
[109]
Editing efficiency
(transfection 
efficiency)
Nonviral vectors (not 
including electroporation)
Need to be further optimized; 
combination of viral vectors and 
nonviral vectors
[16], 
[95]
Systemic delivery Viral and nonviral vectors Difficult to achieve through 
nonviral vectors; tailoring new 
carriers
[16], 
[87]
Targeted delivery Nonviral vectors Viral vectors provide tissue tropism [110]
Table 3. 
Challenges for delivering the CRISPR/Cas9 system and the strategies that respond to these challenges.
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5. Cytotoxicity produced by the CRISPR/Cas9 system and toxic response to 
CRISPR/Cas9 in mammalian cells has become an issue that must be taken into 
account. Recently, there have been reports that DSBs induced by Cas9 triggered a 
P53-dependent toxic response that reduced the editing efficiency when applying 
the CRISPR/Cas9 system to human programmed cells [114, 115]. Corresponding 
studies on pigs have not yet been undertaken, but the human studies provide 
some useful lessons for the development of pig research on genome editing.
6. Using the resulting fetuses or newborns edited by CRISPR/Cas9 for screen-
ing of effective clones is time-consuming and laborious [80]. Probably, the 
method of T7E1 assay for detecting insertion/deletion (INDEL) mutations in 
blastocysts could help researchers to save time and money [80].
5. Conclusion
Over the past few years, genome-editing technology clearly allows scientists to 
produce genetically engineered pigs that are healthier to consume and more resis-
tant to diseases in an efficient way. Nowadays, the use of the CRISPR/Ca9 technique 
on pigs in immunity, autoimmunity, obesity, aging, etc. is increasingly expanding 
and showing advantages over the conventional methods. In addition, another 
version of CRISPR named CRISPR/Cpf1 was discovered in microbes, which fur-
ther expanded the CISPR toolkit, and holds promise to be applied in pig research. 
CRISPR/Ca9-modified pigs are providing a better perspective for understanding 
various aspects of pig biology and are paving the way for advancing the fields of 
basic biology, translational medicine, biomedicine, and drug development.
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